Skip to content


Siliq, Kyntheum (brodalumab) is an antibody pharmaceutical. Brodalumab was first approved as Siliq on 2017-02-15. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-17 receptor A.
Trade Name Kyntheum
Common Name Brodalumab
Indication psoriasis
Drug Class Monoclonal antibodies: fully human, immunomodulating
Get full access now